Halozyme Therapeutics, Inc. (HALO)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Halozyme Therapeutics, Inc. (HALO) is up 3.7% since the beginning of the year. At $70 per share, HALO is trading 15.1% below its 52-week high of $82. Investors who bought $1,000 worth of HALO shares 5 years ago would now be looking at an investment worth $1,769.

Halozyme Therapeutics, Inc. (HALO) has returned 3.74% so far this year and 30.97% over the past 12 months. Looking at the last ten years, HALO has achieved an annualized return of 21.91%, outperforming the S&P 500 Index benchmark, which averaged 13.66% per year.

Based on dividend-adjusted daily data since Mar 16, 2004, HALO's average daily return is +0.12%, while the average monthly return is +2.47%. At this rate, an investment would double in approximately 2.4 years.

Historically, 54% of months were positive and 46% were negative. The best month was Dec 2006 with a return of +178.6%, while the worst month was Jan 2016 at -49.2%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 5 months.

On a daily basis, HALO closed higher 49% of trading days. The best single day was Dec 6, 2006 with a return of +59.6%, while the worst single day was Aug 2, 2012 at -49.8%.

Halozyme Therapeutics, Inc. has an annualized alpha of 18.79%, beta of 1.18, and R2 of 0.15 versus S&P 500 Index. Calculated based on daily prices since March 17, 2004.

• This stock captured 155.04% of S&P 500 Index gains and 129.44% of its losses - amplifying both gains and losses, but participating more in upside than downside.
• R2 of 0.15 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

HALO ranks 67 for risk / return — better than 67% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for Halozyme Therapeutics, Inc. (HALO) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Halozyme Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Halozyme Therapeutics, Inc. was 74.26%, occurring on Dec 4, 2008. Recovery took 795 trading sessions.

The current Halozyme Therapeutics, Inc. drawdown is 14.05%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Halozyme Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Halozyme Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.